Astellas Pharma Inc (ALPMY)

Currency in USD
9.69
-0.08(-0.82%)
Closed·
After Hours
9.690.00(0.00%)
·
ALPMY Scorecard
Full Analysis
High shareholder yield
Earnings results expected in 7 days
Fair Value
Day's Range
9.669.79
52 wk Range
8.3713.14
Key Statistics
Prev. Close
9.69
Open
9.72
Day's Range
9.66-9.79
52 wk Range
8.37-13.14
Volume
193.82K
Average Volume (3m)
166.09K
1-Year Change
-7.01%
Book Value / Share
5.64
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALPMY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.30
Upside
+16.62%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 10 consecutive years

Astellas Pharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Astellas Pharma Inc Company Profile

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. Astellas Pharma Inc. was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Employees
13643

Compare ALPMY to Peers and Sector

Metrics to compare
ALPMY
Peers
Sector
Relationship
P/E Ratio
52.5x17.2x−0.5x
PEG Ratio
0.25−0.370.00
Price/Book
1.8x2.2x2.6x
Price / LTM Sales
1.4x3.0x3.2x
Upside (Analyst Target)
16.6%12.2%42.7%
Fair Value Upside
Unlock25.9%5.8%Unlock

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 11.30
(+16.62% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 28.35%
Dividend Yield
-
Industry Median 2.84%
Annualised payout
-
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Apr 25, 2025
EPS / Forecast
0.2929 / 0.1349
Revenue / Forecast
3.22B / 2.74B
EPS Revisions
Last 90 days

ALPMY Income Statement

People Also Watch

FAQ

What Stock Exchange Does Astellas Pharma Inc Trade On?

Astellas Pharma Inc is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Astellas Pharma Inc?

The stock symbol for Astellas Pharma Inc is "ALPMY."

What Is the Astellas Pharma Inc Market Cap?

As of today, Astellas Pharma Inc market cap is 18.07B.

What Is Astellas Pharma Inc's Earnings Per Share (TTM)?

The Astellas Pharma Inc EPS (TTM) is 28.35.

When Is the Next Astellas Pharma Inc Earnings Date?

Astellas Pharma Inc will release its next earnings report on 29 Jul 2025.

From a Technical Analysis Perspective, Is ALPMY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Astellas Pharma Inc Stock Split?

Astellas Pharma Inc has split 2 times.

How Many Employees Does Astellas Pharma Inc Have?

Astellas Pharma Inc has 13643 employees.

What is the current trading status of Astellas Pharma Inc (ALPMY)?

As of 23 Jul 2025, Astellas Pharma Inc (ALPMY) is trading at a price of 9.69, with a previous close of 9.69. The stock has fluctuated within a day range of 9.66 to 9.79, while its 52-week range spans from 8.37 to 13.14.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.